Third Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System
February 27, 2024 08:00 ET
|
Third Pole Therapeutics
WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and...
Third Pole Therapeutics Announces First Patient Dosed in Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System
December 11, 2023 16:05 ET
|
Third Pole Therapeutics
WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, Inc., a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and...
Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform
December 14, 2022 08:00 ET
|
Third Pole Therapeutics
Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device WALTHAM, Mass., Dec. 14, 2022 (GLOBE...